C
12.39
0.81 (6.99%)
| Previous Close | 11.58 |
| Open | 12.00 |
| Volume | 171,578 |
| Avg. Volume (3M) | 147,950 |
| Market Cap | 580,387,584 |
| Price / Sales | 44.30 |
| Price / Book | 28.39 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Profit Margin | -174.97% |
| Operating Margin (TTM) | -193.39% |
| Diluted EPS (TTM) | -0.550 |
| Quarterly Revenue Growth (YOY) | 11.50% |
| Total Debt/Equity (MRQ) | 12.92% |
| Current Ratio (MRQ) | 3.87 |
| Operating Cash Flow (TTM) | -21.05 M |
AIStockmoo Score
0.3
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 0.25 |
| % Held by Insiders | 40.89% |
| 52 Weeks Range | ||
| Median | 14.00 (12.99%) | |
| Total | 1 Not Rated | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Benchmark | 31 Dec 2025 | 14.00 (12.99%) | Not Rated | 12.39 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2025 | Announcement | CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference |
| 13 Nov 2025 | Announcement | CapsoVision Reports Third Quarter 2025 Financial Results |
| 10 Nov 2025 | Announcement | CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule |
| 03 Nov 2025 | Announcement | CapsoVision Appoints David Garcia as Senior Vice President of Finance |
| 30 Oct 2025 | Announcement | CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |